Stay updated with breaking news from Charlie silver. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Beyond bitcoin: These altcoins are super popular msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Tyler Jacks, Ph.D., after 19 years. The director role will be taken over by Matthew Vander Heiden, M.D., Ph.D., a professor of biology at MIT and a medical oncologist at Dana-Farber Cancer Institute. He became a member of the Koch Institute in 2010 and took over for Jacks on Thursday, MIT said. Jacks will continue to lead the Bridge Project, which unites bioegnineers, cancer scientists and clinical oncologists from the Koch Institute and the Dana-Farber/Harvard Cancer Center. Amie Krause into the role of senior vice president and chief people officer April 2. Since joining the company, Krause has been the driving force behind Atara’s human people department, advocating for employees across the organization. She doubles as a founding leader of Atara’s Women’s Alliance and is part of the Healthcare Businesswomen’s Association. Before signing on with Atara, Krause held several top human resources roles at Amgen, including HR le ....
Press release content from PR Newswire. The AP news staff was not involved in its creation. Mission Bio Announces Yan Zhang as New CEO April 8, 2021 GMT SAN FRANCISCO, April 8, 2021 /PRNewswire/ Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the appointment of Yan Zhang to the role of CEO. Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she drove above-market growth for multiple business lines, including leading the commercial organization in China for Genetic Sciences and Clinical Next-Generation Sequencing divisions and leading the Reproductive Health and Microarray businesses as General Manager. Zhang succeeds current Mission Bio CEO and co-founder Charlie Silver, who will be moving into an advisor role with the company. ....
New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio s Tapestri Platform Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments News provided by Share this article
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, today announced a new study published in Nature Communications using its Tapestri Platform to perform high-throughput single-cell proteogenomic profiling to precisely characterize tumor heterogeneity in three acute myeloid leukemia (AML) patients across multiple treatment time points. In conventional AML studies, DNA sequencing and flow cytometry have been used to assess disease genotype and immunophenotype, respectively. However, because a cell s underlying DNA mutation or co-occurring mutations may not robustly pred ....
New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio's Tapestri Platform prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.